Seres Therapeutics Inc (NASDAQ:MCRB) has a beta value of 2.05 and has seen 2.24 million shares traded in the last trading session. The MCRB stock price is -150.0% off its 52-week high price of $2.05 and 34.15% above the 52-week low of $0.54. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.21 million shares traded. The 3-month trading volume is 3.81 million shares.
The consensus among analysts is that Seres Therapeutics Inc (MCRB) is Buy stock at the moment, with a recommendation rating of 2.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Sporting 0.26% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the MCRB stock price touched $0.82 or saw a rise of 0.83%. Year-to-date, Seres Therapeutics Inc shares have moved -41.29%, while the 5-day performance has seen it change 16.60%. Over the past 30 days, the shares of Seres Therapeutics Inc (NASDAQ:MCRB) have changed -1.83%. Short interest in the company has seen 18.05 million shares shorted with days to cover at 3.48.
Wall Street analysts have a consensus price target for the stock at $1.25, which means that the shares’ value could jump 34.4% from current levels. The projected low price target is $1.25 while the price target rests at a high of $1.25. In that case, then, we find that the current price level is -52.44% off the targeted high while a plunge would see the stock gain -52.44% from current levels.
Seres Therapeutics Inc (MCRB) estimates and forecasts
Figures show that Seres Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -29.15% over the past 6 months, with this year growth rate of -3.37%, compared to 17.50% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 18.22% over the past 5 years.
MCRB Dividends
Seres Therapeutics Inc is expected to release its next earnings report on 2024-Nov-01 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders
Insiders own 13.23% of the company shares, while shares held by institutions stand at 41.25% with a share float percentage of 47.54%. Investors are also buoyed by the number of investors in a company, with Seres Therapeutics Inc having a total of 108.0 institutions that hold shares in the company. The top two institutional holders are FLAGSHIP PIONEERING INC. with over 23.12 million shares worth more than $16.73 million. As of 2024-06-30, FLAGSHIP PIONEERING INC. held 15.8226% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 22.72 million shares as of 2024-06-30. The firm’s total holdings are worth over $16.44 million and represent 15.5489% of shares outstanding.
